|

Swedish Ibrance Registries Insights (SIRI)

RECRUITINGSponsored by Pfizer
Actively Recruiting
SponsorPfizer
Started2020-12-15
Est. completion2026-05-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04654208

Summary

The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

1. One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33)
2. Age ≥18 years at index date

Exclusion Criteria:

There are no exclusion criteria

Conditions3

Breast CancerCancerMalignant Neoplasm of Breast

Interventions1

Palbociclib

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.